Notable Runner: What’s Propelling Cara Therapeutics Inc to Increase So Much?

Notable Runner: What's Propelling Cara Therapeutics Inc to Increase So Much?

The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! About 1.57M shares traded hands or 1.95% up from the average. Cara Therapeutics Inc (NASDAQ:CARA) has risen 35.11% since April 14, 2016 and is uptrending. It has outperformed by 30.42% the S&P500.
The move comes after 8 months positive chart setup for the $335.79M company. It was reported on Nov, 16 by Barchart.com. We have $16.94 PT which if reached, will make NASDAQ:CARA worth $167.90M more.

Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage

Out of 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cara Therapeutics has been the topic of 6 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Needham maintained it with “Buy” rating and $27 target price in Friday, July 24 report. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, October 13. The stock of Cara Therapeutics Inc (NASDAQ:CARA) has “Buy” rating given on Wednesday, November 4 by Cantor Fitzgerald.

According to Zacks Investment Research, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.”

Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.32, from 1.02 in 2016Q1. The ratio is negative, as 27 funds sold all Cara Therapeutics Inc shares owned while 20 reduced positions. 6 funds bought stakes while 27 increased positions. They now own 13.15 million shares or 19.13% less from 16.26 million shares in 2016Q1.
Chesapeake Partners Mngmt Md, a Maryland-based fund reported 960,508 shares. Blackrock Advsr Lc holds 0% or 69,398 shares in its portfolio. Legal & General Group Public Ltd Company accumulated 0% or 3,710 shares. National Bank & Trust Of Montreal Can holds 180 shares or 0% of its portfolio. Pictet Asset Mgmt has 0.02% invested in the company for 775,898 shares. Aqr Capital Ltd Liability Com owns 157,057 shares or 0% of their US portfolio. D E Shaw And holds 0% or 18,773 shares in its portfolio. Teachers Advsr Inc holds 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 30,838 shares. Amer Int Grp Incorporated accumulated 0% or 12,094 shares. Nationwide Fund last reported 20,187 shares in the company. Northern Tru holds 216,644 shares or 0% of its portfolio. Geode Management Limited Com holds 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 119,201 shares. Jacobs Levy Equity Mgmt holds 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 13,100 shares. The California-based Wall Street Assocs has invested 0.37% in Cara Therapeutics Inc (NASDAQ:CARA). Moreover, Wells Fargo And Com Mn has 0% invested in Cara Therapeutics Inc (NASDAQ:CARA) for 5,285 shares.

Another recent and important Cara Therapeutics Inc (NASDAQ:CARA) news was published by Seekingalpha.com which published an article titled: “Cara Therapeutics: A Run-Up Interrupted” on November 07, 2016.

CARA Company Profile

Cara Therapeutics, Inc., incorporated on July 2, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Firm operates through the activities related to the discovery and development of novel therapeutics to treat serious medical conditions, including pain and pruritus segment. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system. The Company’s product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment